Snoop nasal spray 0.1% 15ml №1

Name:
Snoop. Release formSpray. INNK silometazoline. FTG Anticongestive agent – vasoconstrictor (alpha-adrenergic agonist). Composition 1 ml of nasal spray 0.05% contains: active ingredient – xylometazoline hydrochloride – 0.50 mg; other ingredients: sea water – 250.0 mg, potassium dihydrogen phosphate – 0.45 mg, purified water – 754.35 mg. 1 ml nasal spray 0.1% contains: active ingredient – xylometazoline hydrochloride -1.0 mg; other ingredients: sea water – 250.0 mg, potassium dihydrogen phosphate – 0.45 mg, purified water – 753.85 mg.
Description:
Colorless transparent solution. Pharmacotherapeutic group Decongestants and other topical nasal preparations. Sympathomimetics. ATX code: R01AA07. Pharmacological properties Pharmacodynamics Xylometazoline belongs to the group of local vasoconstrictors with alpha-adrenomimetic activity, causes narrowing of the blood vessels of the nasal mucosa, eliminating swelling and hyperemia of the nasal mucosa, restores the patency of the nasal passages, facilitates nasal breathing. The effect of the drug occurs within a few minutes after its application and lasts for several hours (average 6-8 hours). Pharmacokinetics When applied topically, the drug is practically not absorbed, so its concentration in the blood plasma is very low (not determined by modern analytical methods). Indications for use Acute respiratory diseases with symptoms of rhinitis (runny nose), acute allergic rhinitis, hay fever, sinusitis, eustachitis, otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa), to facilitate rhinoscopy and other diagnostic manipulations in the nasal passages. Contraindications Hypersensitivity to the components of the drug, angle-closure glaucoma, atrophic rhinitis, dry rhinitis, thyrotoxicosis, transsphenoidal hypophysectomy or other surgical interventions on the meninges (in history), children under 12 years of age (for 0.1% solution), children under 2 years of age ( for 0.05% solution). Dosage and administration Before use, it is necessary to clear the nasal passages (blow your nose), remove the protective cap from the vial. Before the first use or after a long break in use, press the spray valve several times until a dispersed jet appears. When spraying into the nostril, the bottle should be in a vertical position, pressing the valve is done while inhaling. After use, it is recommended to clean the nozzle and close the vial with a protective cap. Snoop® Nasal Spray 0.05% Children aged 2 to 12 years: 1 spray in each nostril (may be repeated if necessary), up to three times a day. Snoop® Nasal Spray 0.1% Adults and children over 12 years old: 1 spray in each nostril (may be repeated if necessary), up to three times a day. The drug should not be used more than three times a day, the duration of the course of treatment is not more than 7 days. Side effect Criteria for the frequency of occurrence of adverse reactions: very often (≥ 1/10), often (≥ 1/100, < 1/10), infrequently (≥ 1/1000, < 1/100), rarely (≥ 1/10000, < 1/1.000), very rare (< 1/1.0000). Heart disorders: infrequently - palpitations, tachycardia; very rarely - arrhythmia. Nervous system disorders: very rarely - headache, convulsions (especially in children). Respiratory, chest and mediastinal disorders: often - burning and dryness of the nasal mucosa, sneezing; infrequently - swelling of the mucous membrane of the nasal cavity, nosebleeds; very rarely - apnea (noted in young children and newborns). Vascular disorders: infrequently - arterial hypertension. General disorders: increased fatigue (drowsiness, sedation). Immune system disorders: infrequently - hypersensitivity reactions (angioneurotic edema, skin rash, itching). Mental disorders: very rarely - anxiety, insomnia, hallucinations (mainly in children). In the event of adverse reactions, including those not listed in this leaflet, you should stop using the drug and consult a doctor. Overdose Symptoms of stimulation of the central nervous system are anxiety (feeling of fear, anxiety), agitation, hallucinations, convulsions. Symptoms of depression of the central nervous system are a decrease in body temperature, lethargy, drowsiness, coma. The following additional symptoms may occur: miosis, mydriasis, sweating, fever, pallor, cyanosis, nausea, vomiting, tachycardia, bradycardia, cardiac arrhythmia, cardiac arrest, arterial hypertension or hypotension, pulmonary edema, respiratory failure and apnea. Overdose (especially in children) often leads to the following effects of the central nervous system: convulsions, coma, bradycardia, apnea, arterial hypertension, which may be replaced by arterial hypotension. Treatment: There is no specific antidote. Treatment is symptomatic, under medical supervision. Vasoconstrictors are contraindicated. In severe overdose - intensive care in a hospital. Precautions The drug should be used with caution in patients with severe cardiovascular diseases (including coronary heart disease, arterial hypertension), hyperthyroidism, diabetes mellitus, pheochromocytoma, prostatic hyperplasia, porphyria, hypersensitivity to adrenergic drugs, accompanied by insomnia, dizziness, tremor, cardiac arrhythmias, increased blood pressure while taking monoamine oxidase (MAO) inhibitors and other drugs that increase blood pressure. Do not use for more than 7 days in a row and exceed the recommended doses, especially in children and elderly patients: prolonged and excessive use of vasoconstrictors can lead to the development of drug-induced rhinitis, manifested by increased secretion of mucus and swelling of the nasal mucosa. Use in childrenSnoop® nasal spray 0.05% is contraindicated for use in children under 2 years of age; used in children from 2 to 12 years. Snoop® nasal spray 0.1% is contraindicated for use in children under 12 years of age; used in children over 12 years of age. The use of the drug in children should be carried out under the supervision of adults. Recommended daily doses of the drug and the duration of the course of treatment are determined by the attending physician. Use during pregnancy or lactation Due to the vasoconstrictive properties of the drug, as a precaution, it should not be used during pregnancy. It has not been established whether xylometazoline passes into breast milk when applied topically. The use of the drug during breastfeeding is possible only on the advice of a doctor, if the expected benefit to the mother outweighs the potential risk to the child. Influence on the ability to drive vehicles and mechanisms When used in recommended doses, the drug does not affect driving, working with mechanisms and performing potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Interaction with other drugs When using the drug in recommended doses, systemic effects are negligible. An increase in the systemic effects of xylometazoline, especially in case of an overdose, can be observed when used together with tricyclic antidepressants, MAO inhibitors (including within 14 days after their withdrawal) and other drugs that increase blood pressure. Upakovka15 ml nasal spray (150 doses) in a polyethylene bottle with a spray valve (ZK system). 1 bottle with instructions for use of the drug is placed in a cardboard box. Shelf life 5 years. The contents of the vial are sterile, without preservatives. Do not use after the expiration date. Storage conditions At a temperature not higher than 25 °C. Snoop® nasal spray 0.05% After opening the vial, the drug should be used within 3 months. Snoop® nasal spray 0.1% After opening the vial, the drug must be used within 12 months. Keep out of the reach of children. Terms of dispensing from pharmaciesWithout a prescription. Buy Snoop nasal spray 0.1% 15ml №1 Price for Snoop nasal spray 0.1% 15ml №1Instruction for use for Snoop nasal spray 0.1% 15ml №1